These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3485443)

  • 21. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody.
    Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG
    Blood; 1982 Mar; 59(3):664-70. PubMed ID: 7059674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor VII activity and antigen in haemophilia B variants.
    Mazzucconi MG; Bertina RM; Romoli D; Orlando M; Avvisati G; Mariani G
    Thromb Haemost; 1980 Feb; 43(1):16-9. PubMed ID: 7404475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of an occult inhibitor to factor IX in a haemophilia B patient.
    Miller CH; Orstavik KH; Hilgartner MW
    Br J Haematol; 1985 Oct; 61(2):329-38. PubMed ID: 4041376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunoradiometric assay of factor IX antigen using monoclonal antibody and classification of hemophilia B].
    Yoshioka A; Ohkubo Y; Nishino M; Sakai T; Sugimoto M; Nishimura T; Tanaka I; Fukui H
    Rinsho Ketsueki; 1985 Feb; 26(2):159-65. PubMed ID: 4021109
    [No Abstract]   [Full Text] [Related]  

  • 25. The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa.
    Aktimur A; Gabriel MA; Gailani D; Toomey JR
    J Biol Chem; 2003 Mar; 278(10):7981-7. PubMed ID: 12496253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
    Bertina RM; van der Linden IK; Mannucci PM; Reinalda-Poot HH; Cupers R; Poort SR; Reitsma PH
    J Biol Chem; 1990 Jul; 265(19):10876-83. PubMed ID: 2162822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitive solid phase enzyme immunoassay for factor IX antigen and classification of hemophilia B.
    Takamatsu J; Kamiya T; Ogata K; Sugihara T; Koie K; Kato K
    Haemostasis; 1983; 13(1):9-16. PubMed ID: 6341181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX.
    Sinha D; Seaman FS; Walsh PN
    Biochemistry; 1987 Jun; 26(13):3768-75. PubMed ID: 3498513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H- and 125I-labeled factor IX.
    Bajaj SP; Rapaport SI; Russell WA
    Biochemistry; 1983 Aug; 22(17):4047-53. PubMed ID: 6604546
    [No Abstract]   [Full Text] [Related]  

  • 30. An immunoradiometric assay for factor VIII related antigen (VIIIRAg) using two monoclonal antibodies-comparison with polyclonal rabbit antibodies for use in von Willebrand's disease diagnosis.
    Sultan Y; Avner P; Maisonneuve P; Arnaud D; Jeanneau C
    Thromb Haemost; 1984 Dec; 52(3):250-2. PubMed ID: 6442468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII clotting antigen (VIIICAg) in haemophilia measured by two immunoradiometric assays (IRMA) using different antibodies, and the measurement of inhibitors to procoagulant factor VIII (VIIIC) by IRMA.
    Furlong RA; Peake IR; Bloom AL
    Br J Haematol; 1981 Aug; 48(4):643-50. PubMed ID: 6791678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy.
    Takahashi H; Hanano M; Hayashi S; Arai Y; Yoshino N; Takakuwa E; Tatewaki W; Nagayama R; Takizawa S; Shibata A
    Tohoku J Exp Med; 1986 Aug; 149(4):351-7. PubMed ID: 3775760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prenatal diagnosis of hemophilia B by an immunoradiometric assay of factor IX.
    Holmberg L; Gustavii B; Cordesius E; Kristoffersson AC; Ljung R; Löfberg L; Strömberg P; Nilsson IM
    Blood; 1980 Sep; 56(3):397-401. PubMed ID: 7407407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical characterisation of the haemophilias on the Witwatersrand.
    van Wijk MG; Cohn R; Hartman E; Atkinson PM
    S Afr Med J; 1989 Oct; 76(7):318-20. PubMed ID: 2508247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An agarose plate method for detecting alloantisera to coagulant factor IX and factor IX antigen.
    Reisner HM; Strand EA; Chung KS; Roberts HR
    Br J Haematol; 1980 Feb; 44(2):313-21. PubMed ID: 7378302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Properties, variants, and applications of the immunoradiometric assay method.
    Miles LE
    Ric Clin Lab; 1975; 5(1):59-72. PubMed ID: 772782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A two-site, monoclonal antibody-based immunoassay for von Willebrand factor--demonstration that vWF function resides in a conformational epitope.
    Chand S; McCraw A; Hutton R; Tuddenham EG; Goodall AH
    Thromb Haemost; 1986 Jun; 55(3):318-24. PubMed ID: 2428124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of monoclonal antibodies in an enzyme immunoassay for factor VIII-related antigen.
    Bradley LA; Franco EL; Reisner HM
    Clin Chem; 1984 Jan; 30(1):87-92. PubMed ID: 6418411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a factor IX binding site on the third apple domain of activated factor XI.
    Sun Y; Gailani D
    J Biol Chem; 1996 Nov; 271(46):29023-8. PubMed ID: 8910554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and chemical synthesis of a substrate-binding site for factor IX on coagulation factor XIa.
    Baglia FA; Jameson BA; Walsh PN
    J Biol Chem; 1991 Dec; 266(35):24190-7. PubMed ID: 1748688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.